Vial Thomas auteur aut IRD Tan W. L. auteur aut IRD Deharo Eric auteur aut IRD Missé Dorothée auteur aut IRD Marti G. auteur aut IRD Pompon Julien auteur aut IRD text journalArticle eng text/pdf born digital access Dengue virus (DENV) subdues cell membranes for its cellular cycle by reconfiguring phospholipids in humans and mosquitoes. Here, we determined how and why DENV reconfigures phospholipids in the mosquito vector. By inhibiting and activating the de novo phospholipid biosynthesis, we demonstrated the antiviral impact of de novo-produced phospholipids. In line with the virus hijacking lipids for its benefit, metabolomics analyses indicated that DENV actively inhibited the de novo phospholipid pathway and instead triggered phospholipid remodeling. We demonstrated the early induction of remodeling during infection by using isotope tracing in mosquito cells. We then confirmed in mosquitoes the antiviral impact of de novo phospholipids by supplementing infectious blood meals with a de novo phospholipid precursor. Eventually, we determined that phospholipid reconfiguration was required for viral genome replication but not for the other steps of the virus cellular cycle. Overall, we now propose that DENV reconfigures phospholipids through the remodeling cycle to modify the endomembrane and facilitate formation of the replication complex. Furthermore, our study identified de novo phospholipid precursor as a blood determinant of DENV human-to-mosquito transmission. specialized mosquito dengue metabolomics replication phospholipid 052 050 020 117 44 27627-27636 2020 0027-8424 https://www.documentation.ird.fr/hor/fdi:010079956 10.1073/pnas.2015095117 0027-8424 [F B010079956] https://www.documentation.ird.fr/hor/fdi:010079956 https://www.documentation.ird.fr/intranet/publi/2020/11/010079956.pdf Accès réservé (Intranet de l'IRD) IRD - Base Horizon / Pleins textes 2020-12-08 2025-02-24 fdi:010079956 fre